Overall, MCT1 was identified as a poor prognostic factor in Hodgkin and Non-Hodgkin lymphoma, head and neck cancer, soft tissue sarcoma, renal cell carcinoma, bladder cancer, osteosarcoma, breast cancer, gastrointestinal stromal tumours, oral cavity tumours, prostate adenocarcinoma, melanoma, gastric cancer, oesophagal squamous cell carcinoma, endometrial cancer and adrenocortical carcinoma. Here, SLC16A1 is linked to breast carcinoma.